Novo Shares Hits 9-Month Low as 2025 Guidance Underwhelms
MILAN (Reuters) - Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as underwhelming guidance for next year overshadowed strong ...
The Focus on MSN23m
People who are desperate to take Ozempic-like drugs are at 'risk,’ warns FDA
The rush for weight loss drugs like Wegovy and diabetes drugs like Ozempic (which is also used for weight loss) has drained ...